Dual-targeting BCMA/CD19 CAR T cells with asymmetric 4-1BB/CD28-YMFM costimulation in relapsed/refractory multiple myeloma: a phase 1/2 trial with single-cell profiling of extramedullary disease

BACKGROUND: Extramedullary disease (EMD) predicts poor outcomes after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM). KQ-2003 is a bicistronic BCMA/CD19 CAR T-cell product incorporating 4-1BB and CD28-YMFM costimulatory domains. We assessed its activity and intralesional biology, focusing on EMD. METHODS: sensitivity). Progression-free survival (PFS) was analyzed using Kaplan-Meier and Cox methods. Longitudinal single-cell RNA sequencing profiled one patient's infusion product, serial blood, and spatially distinct EMD biopsies. RESULTS: Patients had received a median of five prior lines; 18 (75.0%) were triple-class refractory, six (25.0%) penta-refractory, 23 (95.8%) had high-risk cytogenetics, and 15 (62.5%) had EMD. All 20 patients with measurable hematologic disease achieved hematologic responses (18 [90.0%] complete/stringent complete); IMWG-defined overall response rate was 95.0%. Fourteen (93.3%) of 15 EMD patients achieved metabolic responses (13 [86.7%] complete). Among 19 baseline MRD-positive patients, 12 (63.2%) became MRD-negative by month 6; 10 and six also had documented negativity at months 12 and 24, respectively. At 29.2 months' median follow-up, median PFS was 24.0 months (95% CI, 15.0-not reached); no significant difference was detected by baseline EMD status (HR, 0.92; P = 0.89). Among the 21 trial participants, grade ≥ 3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in one (4.8%) and two (9.5%), respectively; two treatment-related fatal pneumonias occurred. Single-patient longitudinal profiling revealed proliferating lesion-infiltrating CAR T cells with increased CCL3/CCL4 expression and tumor-cell apoptotic and necroptotic transcriptional programs. Trajectory analysis suggested transcriptional links between tissue effectors and circulating CCL5-positive memory-like CAR T cells. CellChat predicted BCMA-related tumor-microenvironment interactions and immune-cell interactions involving circulating CAR T cells. CONCLUSIONS: KQ-2003 produced deep, durable hematologic and metabolic responses in heavily pretreated, high-risk RRMM, including EMD. Intralesional profiling identified CAR T-cell proliferation, tumor-cell death-associated programs, and candidate microenvironmental interactions. These findings warrant further evaluation of this dual-targeting strategy in EMD. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04714827; registered 19 January 2021.

Authors

Institutions

Publication Details

Journal
Journal of Hematology & Oncology
Published
2026-11-18
DOI
https://doi.org/10.1186/s13045-026-01870-y
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dual-targeting BCMA/CD19 CAR T cells with asymmetric 4-1BB/CD28-YMFM costimulation in relapsed/refractory multiple myeloma: a phase 1/2 trial with single-cell profiling of extramedullary disease

Xiaoran Mei, 吴国祥, Weijun Fu, Xiaomei Chen et al.
1 links
Journal of Hematology & Oncology
CAR-T cell therapy research
article

Dual-targeting BCMA/CD19 CAR T cells with asymmetric 4-1BB/CD28-YMFM costimulation in relapsed/refractory multiple myeloma: a phase 1/2 trial with single-cell profiling of extramedullary disease

Xiaoran Mei, 吴国祥, Weijun Fu, Xiaomei Chen, Kaili Chen, Dan Li, Chunchen Yang, Ruixue Ma, Xing Xiao, Tao Guan, Can He, Hui Yuan, Yaqin Lu, Liping Su, Jin Zhao, Xianghai Cai, Fang Feng, Tao Zhou, Zhiyou Zhou, Li Ma, Liangyu Xie, Lu Li, Min Bai, Hua Jiang, Xiaoping Ye, Hao Wu
article en

Abstract

BACKGROUND: Extramedullary disease (EMD) predicts poor outcomes after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM). KQ-2003 is a bicistronic BCMA/CD19 CAR T-cell product incorporating 4-1BB and CD28-YMFM costimulatory domains. We assessed its activity and intralesional biology, focusing on EMD. METHODS: sensitivity). Progression-free survival (PFS) was analyzed using Kaplan-Meier and Cox methods. Longitudinal single-cell RNA sequencing profiled one patient's infusion product, serial blood, and spatially distinct EMD biopsies. RESULTS: Patients had received a median of five prior lines; 18 (75.0%) were triple-class refractory, six (25.0%) penta-refractory, 23 (95.8%) had high-risk cytogenetics, and 15 (62.5%) had EMD. All 20 patients with measurable hematologic disease achieved hematologic responses (18 [90.0%] complete/stringent complete); IMWG-defined overall response rate was 95.0%. Fourteen (93.3%) of 15 EMD patients achieved metabolic responses (13 [86.7%] complete). Among 19 baseline MRD-positive patients, 12 (63.2%) became MRD-negative by month 6; 10 and six also had documented negativity at months 12 and 24, respectively. At 29.2 months' median follow-up, median PFS was 24.0 months (95% CI, 15.0-not reached); no significant difference was detected by baseline EMD status (HR, 0.92; P = 0.89). Among the 21 trial participants, grade ≥ 3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in one (4.8%) and two (9.5%), respectively; two treatment-related fatal pneumonias occurred. Single-patient longitudinal profiling revealed proliferating lesion-infiltrating CAR T cells with increased CCL3/CCL4 expression and tumor-cell apoptotic and necroptotic transcriptional programs. Trajectory analysis suggested transcriptional links between tissue effectors and circulating CCL5-positive memory-like CAR T cells. CellChat predicted BCMA-related tumor-microenvironment interactions and immune-cell interactions involving circulating CAR T cells. CONCLUSIONS: KQ-2003 produced deep, durable hematologic and metabolic responses in heavily pretreated, high-risk RRMM, including EMD. Intralesional profiling identified CAR T-cell proliferation, tumor-cell death-associated programs, and candidate microenvironmental interactions. These findings warrant further evaluation of this dual-targeting strategy in EMD. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04714827; registered 19 January 2021.

Journal of Hematology & OncologyVol. 19(1)
Tongji University (CN), Shanxi Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Shanxi Provincial Cancer Hospital (CN)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon